A recent study by Pera et al. reported that an epigenetic drug and inhibitor of lysine deacetylase (KDAC), panobinostat, elevates choline metabolism and induces CHKα up-regulation in DLBCL cells, leading to an increased reliance on CHKα for survival in these cells [83]. Here, CHKA is linked to diffuse large B-cell lymphoma.